¥ê¥ó¥¯½¸
¥á¥¤¥ó | ÅÐÏ¿¤¹¤ë | ¿Íµ¤¥µ¥¤¥È (top10) | ¹âɾ²Á¥µ¥¤¥È (top10) | ¤ª¤¹¤¹¤á¥µ¥¤¥È (7) | Áê¸ß¥ê¥ó¥¯¥µ¥¤¥È (1) |
¥«¥Æ¥´¥ê°ìÍ÷ | RSS/ATOM Âбþ¥µ¥¤¥È (18) | RSS/ATOM µ»ö (66078) | ¥é¥ó¥À¥à¥¸¥ã¥ó¥× |
RSS/ATOM µ»ö (66078)
¤³¤³¤Ëɽ¼¨¤µ¤ì¤Æ¤¤¤ë RSS/ATOM µ»ö¤ò RSS ¤È ATOM ¤ÇÇÛ¿®¤·¤Æ¤¤¤Þ¤¹¡£
ÊÆUltragenyx¼Ò¤ÎCEO¡¢Âè°ì»°¶¦¤¬Æ³Æþ¤·¤¿AAV¤ÎÀ½Â¤µ»½Ñ¤ÎÍøÅÀ¤Ê¤É¤òÀâÌÀ from Æü·Ð¥Ð¥¤¥ª¥Æ¥¯ONLINE (2023-3-31 7:00) |
¡¡ÊÆUltragenyx Pharmaceutical¼Ò¤ÎÆüËÜË¡¿Í¤Ç¤¢¤ëUltragenyx Japan¤Ï¡¢2023ǯ3·î30Æü¡¢Æ±¼Ò¤ÎÁ϶ȼԤǤ¢¤ëEmil D. Kakkis CEO¤ÎÍèÆü¤Ë¤¢¤ï¤»¤Æµ¼Ô²ñ¸«¤ò³«ºÅ¡£Kakkis CEO¤Ï¡¢°äÅÁ»Ò¼£ÎŸþ¤±¤Î¥¢¥Ç¥Î¿ïȼ¥¦¥¤¥ë¥¹¡ÊAAV¡Ë¥Ù¥¯¥¿¡¼¤ÎÀ½Â¤´ðÈ×µ»½Ñ¤Ç¤¢¤ë¡ÖPinnacle PCL¡×¤ÎÍøÅÀ¤Ê¤É¤Ë¤Ä¤¤¤ÆÀâÌÀ¤·¤¿¡£
|
¥¦¥§¥ë¥Í¥¹¥Õ¡¼¥É¤ÎºÇ¿·¥°¥í¡¼¥Ð¥ë¥È¥ì¥ó¥É¡¢±ÉÍÜ¡¦·ò¹¯¿©ÉʻԾì¤Ë¤ª¤±¤ë5¤Ä¤Î¥á¥¬¥È¥ì¥ó¥É¤È10¤Î¥¡¼¥È¥ì¥ from Æü·Ð¥Ð¥¤¥ª¥Æ¥¯ONLINE (2023-3-31 7:00) |
¡¡¥¦¥§¥ë¥Í¥¹¥Õ¡¼¥É¡Ê±ÉÍÜ¡¦·ò¹¯¿©ÉÊ¡Ë»º¶È¤Î»ö¶È´Ä¶¤ÏÆü¡¹¡¢¹ï¡¹¤ÈÊѤï¤ê³¤±¤Æ¤¤¤ë¡£¿·À½Éʤγ«È¯¤ä¥Þ¡¼¥±¥Æ¥£¥ó¥°Àïά¤ÎΩ°Æ¤Ë¤Ï¡¢»Ô¾ìÊѲ½¤ä¥È¥ì¥ó¥É¤òÀè¼è¤ê¤·¤ÆʬÀϤ¹¤ë¤³¤È¤¬½ÅÍפǤ¢¤ë¡£É®¼Ô¤¬Âåɽ¤ò̳¤á¤ë¥°¥í¡¼¥Ð¥ë¥Ë¥å¡¼¥È¥ê¥·¥ç¥ó¥°¥ë¡¼¥×¡ÊÅìµþ¡¦ËÅç¡Ë¤Ï¡¢²áµî20ǯ¶á¤¯¤Ë¤ï¤¿¤Ã¤Æ¥¦¥§¥ë¥Í¥¹¥Õ¡¼¥É¶È³¦¤Î¥³¥ó¥µ¥ë¥Æ¥£¥ó¥°¤ò¼ê³Ý¤±¤Æ¤¤¿¡£ËÜ¥³¥é¥à¤Ç¤Ï¡¢¤³¤Î¶È³¦¤ÎºÇ¿·¥È¥ì¥ó¥É¤ò¤ªÆϤ±¤·¡¢¥¦¥§¥ë¥Í¥¹¥Õ¡¼¥É¤Ç¥Ó¥¸¥Í¥¹¤òŸ³«¤·¤è¤¦¤È¹Í¤¨¤Æ¤¤¤ëÊý¡¹¤Î»²¹Í¤Ë¤·¤Æ¤¤¤¿¤À¤¤¿¤¤¤È»×¤¦¡£
|
¥Ð¥¤¥ª¥Ó¥¸¥Í¥¹¤ò¤È¤ê¤Þ¤¯¥È¥ì¥ó¥É²òÀâ¡Ê5¡Ë¡¢Äó·È¡¦Çã¼ý¤Ç¶¥Á褬·ã²½¤¹¤ë¥á¥¬¥Õ¥¡¡¼¥Þ¤Î¥Ñ¥¤¥×¥é¥¤¥óÀïά from Æü·Ð¥Ð¥¤¥ª¥Æ¥¯ONLINE (2023-3-31 7:00) |
¡¡¾å»Ô¡Ê»Ô¾ìÅêÆþ¡Ë¤Þ¤Ç¤Î´ü´Ö¤¬Èó¾ï¤ËŤ¤¿·Ìô³«È¯¤Ë¤ª¤¤¤Æ¡¢À¤³¦¤ÎÂç¼êÀ½Ìô´ë¶È¤Ï»ñËÜÎϤòÀ¸¤«¤·¤ÆƳÆþ¤·¤¿µ»½Ñ¤ä¸õÊäÉʤò´ð¤ËÎ×¾²³«È¯¤·¡¢¥¥ã¥Ã¥·¥å¤ò²ó¼ý¤¹¤ë¥Ó¥¸¥Í¥¹¥â¥Ç¥ë¤ò´ðËܤȤ·¤Æ¤¤¤ë¡£¿·Ìô³«È¯¤Î³ݤ«¤ê¤È¤Ê¤ëµ»½Ñ¤ÎÌÜÍø¤¤È»ñËÜÎϤ¬¤â¤Î¸À¤¦À¤³¦¤À¡£¤³¤¦¤·¤¿Ãæ¡¢µ¬ÌϤÇÎô¤ëÆüËܤÎÀ½Ìô´ë¶È¤Ï¤É¤Î¤è¤¦¤ËÀ¸¤»Ä¤Ã¤Æ¤¤¤¯¤Î¤À¤í¤¦¤«¡©°åÎŤÎÀ¤³¦¤Ç¤Ï¿ÇÃǵ»½Ñ¤â¿ÊŸ¤·¡¢¼£ÎŤˤâ¸ú²Ì¤òȯ´ø¤¹¤ë¥¢¥×¥ê¤âÂæƬ¤·¤Æ¤¤Æ¤¤¤ë¡£À½Ìô´ë¶È¤Î¼ç¼´¤Ïº£¸å¤â¿·Ìô¤ÎÁÏÀ½¤Ç¤¢¤ê³¤±¤ë¤È»×¤ï¤ì¤ë¤¬¡¢¿·¤¿¤Êµ»½Ñ¤¬¼¡¡¹¤ÈÅо줷¡¢°åÎŤؤδؤï¤êÊý¤¬Â¿ÍͲ½¤·¤Æ¤¤¤¯¤Î¤Ï´Ö°ã¤¤¤Ê¤¤¡£¤½¤¦¤·¤¿ÊѲ½¤ÎÃæ¤Ç¡¢¼«Ê¬¤¿¤Á¤Ï¤É¤¦¤¢¤ê¤¿¤¤¤Î¤«¡£¤½¤ÎÍýÁÛ¤ò¼Â¸½¤¹¤ë¤¿¤á¤Ë¡¢¤É¤³¤ËÅê»ñ¤¹¤Ù¤¤Ê¤Î¤«¡£¤½¤¦¤·¤¿»ëÅÀ¤¬º£¸å¡¢À½Ìô´ë¶È¤Ë¤Ï¤Þ¤¹¤Þ¤¹µá¤á¤é¤ì¤Æ¤¤¤¯¤À¤í¤¦¡£
|
ž¼Ì°ø»ÒɸŪÌô¤ÎÊÆFlare¼Ò¡¢Ç¢Ï©¾åÈ餬¤ó¤ÎÎ×¾²Æþ¤ê¤Ë¸þ¤±161²¯±ßĴã from Æü·Ð¥Ð¥¤¥ª¥Æ¥¯ONLINE (2023-3-31 7:00) |
¡¡ÊÆFlare Therapeutics¼Ò¤Ï2023ǯ3·î22Æü¡¢¥·¥ê¡¼¥ºB¥é¥¦¥ó¥É¤ÇÌÜɸ³Û¤òĶ¤¨¤ë1²¯2300Ëü¥É¥ë¡ÊÌó161²¯±ß¡Ë¤òĴ㤷¤¿¤Èȯɽ¤·¤¿¡£Ç¢Ï©¾åÈ餬¤ó¤Î¼çÍמ¼Ì°ø»Ò¤Ç¤¢¤ë¥Ú¥ë¥ª¥¥·¥½¡¼¥àÁý¿£°ø»Ò³èÀ²½¼õÍÆÂÎ¥¬¥ó¥Þ¡ÊPPAR¦Ã¡Ë¤òÁ˳²¤¹¤ë¥ê¡¼¥É³«È¯ÉÊ¡ÊFX-909¡Ë¤ÎÎ×¾²»î¸³¤Ë¸þ¤±»ñ¶â¤ò³èÍѤ¹¤ë¤Û¤«¡¢¸å³Éʤγ«È¯¿ä¿Ê¤Ë¤â»ñ¶â¤òÅêÆþ¤¹¤ë¡£
|
ÂçºåÂç¤ÈÅçÄÅÀ½ºî½ê¤Ê¤É´ë¶È4¼Ò¡¢ÇÝÍÜÆù³«È¯¤Ç¥³¥ó¥½¡¼¥·¥¢¥àÀßΩ from Æü·Ð¥Ð¥¤¥ª¥Æ¥¯ONLINE (2023-3-30 7:00) |
¡¡ÂçºåÂç³ØÂç³Ø±¡¹©³Ø¸¦µæ²Ê¡¢ÅçÄÅÀ½ºî½ê¡¢°ËÆ£¥Ï¥àÊƵץۡ¼¥ë¥Ç¥£¥ó¥°¥¹¡Ê°Ê²¼°ËÆ£¥Ï¥àÊƵסˡ¢ÆÌÈÇ°õºþ¡¢¥·¥°¥Þ¥¯¥·¥¹¤Ï2023ǯ3·î29Æü¡¢ÇÝÍÜÆù¤Î»ö¶È²½¤Ë¸þ¤±¤¿¥³¥ó¥½¡¼¥·¥¢¥à¤òÀßΩ¤·¤¿¡£2025ǯ¤ÎÆüËܹñºÝÇîÍ÷²ñ¡ÊÂçºåËüÇî¡Ë¤Ç¤ÎÀ½Â¤ÀßÈ÷Ÿ¼¨¤Ê¤É¤òÌܻؤ·¡¢¥¿¥Ã¥°¤òÁȤó¤ÇËܳʳ«È¯¤Ë¾è¤ê½Ð¤¹¡£
|
ºÆÀ¸°åÎųزñ2023¡ÊÀ½Â¤¼«Æ°²½¡Ë¡§»ºÁí¸¦¡¦²ÆÌܻᡢÈÆÍÑÀ¥í¥Ü¥Ã¥È¤Î²ÁÃͤò¶¯Ä´ from Æü·Ð¥Ð¥¤¥ª¥Æ¥¯ONLINE (2023-3-30 7:00) |
¡¡Âè22²óÆüËܺÆÀ¸°åÎųزñÁí²ñ¡Ê²ñ´ü¡§2023ǯ3·î23Æü¡Á25Æü¡Ë¤Ç¡¢¥·¥ó¥Ý¥¸¥¦¥à¡ÖºÆÀ¸°åÎŤ˻ñ¤¹¤ë¥í¥Ü¥Ã¥È³èÍѤȥǡ¼¥¿½¸ÀѤθ½¾õ¡×¤¬3·î24Æü¤Ë³«¤«¤ì¤¿¡£»º¶Èµ»½ÑÁí¹ç¸¦µæ½ê¼óÀʸ¦µæ°÷¤Î²ÆÌÜÅ°»á¤Ï¡¢ÈÆÍѥҥȷ¿¥í¥Ü¥Ã¥È¡Ö¤Þ¤Û¤í¡×¤Î¶¯¤ß¤È¡¢ºÙ˦ÇÝÍܤο·¤¿¤Ê¼«Æ°²½¼êË¡¤Ë¤Ä¤¤¤Æ¹Ö±é¤·¤¿¡£ÂçºåÂç³ØÂç³Ø±¡¹©³Ø¸¦µæ²Ê¤Îã·Æ£½¼¹°ÆÃǤ½Ú¶µ¼ø¤Ï¼êºî¶È¤Î¥Ö¥ì¤òÀö¤¤½Ð¤¹¼êË¡¡¢µª¥Î²¬ÀµÇ¼ø¤ÏºÙ˦À½Â¤¥×¥í¥»¥¹¤Î¥·¥ß¥å¥ì¡¼¥¿¡¼¹½ÃۤˤĤ¤¤ÆÏä·¤¿¡£
|
°åÎŵ¡´ï¡¦Âγ°¿ÇÃÇÌôÉô²ñ¡¢ÊÛ¼þ°ÏµÕή¤ò·ÐÈé½èÃ֤ǻߤá¤ë°åÎŵ¡´ï¤ò¾µÇ§Î»¾µ from Æü·Ð¥Ð¥¤¥ª¥Æ¥¯ONLINE (2023-3-30 7:00) |
¡¡¸üÀ¸Ï«Æ¯¾Ê¤Ï2023ǯ3·î27Æü¡¢°åÎŵ¡´ï¡¦Âγ°¿ÇÃÇÌôÉô²ñ¤ò³«¤¡¢ÆüËܥ饤¥Õ¥é¥¤¥ó¤ÎÊÛ¼þ°ÏµÕήÊĺ¿¥»¥Ã¥È¤Î¿·µ¬¾µÇ§¤òλ¾µ¤·¤¿¡£
|
ÊÆGilead¼Ò¡¢IRAK4¤ÎɸŪÃÁÇò¼Áʬ²òͶƳÌô¤òÊÆNurix¼Ò¤«¤éƳÆþ¥ª¥×¥·¥ç¥ó¹Ô»È from Æü·Ð¥Ð¥¤¥ª¥Æ¥¯ONLINE (2023-3-30 7:00) |
¡¡ÊÆGilead Sciences¼Ò¤Ï2023ǯ3·î20Æü¡¢ÊÆNurix Therapeutics¼Ò¤È2019ǯ¤Ë·ë¤ó¤À·ÀÌó¤Ë´ð¤Å¤¯¥ª¥×¥·¥ç¥ó¸¢¤ò¹Ô»È¤·¡¢IRAK4¡ÊInterleukin 1 Receptor Associated Kinase 4¡Ë¤òɸŪ¤È¤¹¤ë2²Á¤ÎÃÁÇò¼Áʬ²òͶƳÌô¸õÊä¤Ç¤¢¤ëNX-0479¤Ë¤Ä¤¤¤Æ¡¢ÆÈÀêŪ¤Ê¥é¥¤¥»¥ó¥¹¤ò³ÍÆÀ¤¹¤ë¤Èȯɽ¤·¤¿¡£Gilead¼Ò¤Ï¤³¤ÎÀ½ÉʸõÊä¤Î³«È¯Ì¾¤òGS-6791¤È¤·¤¿¡£
|
OIST¡¢ÅìÂç¤È¶¦Æ±³«È¯¤·¤¿¥µ¥ó¥´¤Î´Ä¶DNAʬÀϤÇÍÍÑÀ¤ò³Îǧ from Æü·Ð¥Ð¥¤¥ª¥Æ¥¯ONLINE (2023-3-30 7:00) |
¡¡²Æì²Ê³Øµ»½ÑÂç³Ø±¡Âç³Ø¡ÊOIST¡Ë¤Ï2023ǯ3·î28Æü¡¢ÅìµþÂç³Ø¤È¶¦Æ±³«È¯¤·¤Æ¤¤¿¥µ¥ó¥´¤Î´Ä¶DNAʬÀÏË¡¤Ë¤Ä¤¤¤Æ¡¢ÍÍÑÀ¤ò³Îǧ¤·¤¿¤Èȯɽ¤·¤¿¡£²ÆìËÜÅç¤ËÀ¸Â©¤¹¤ë¥µ¥ó¥´¤Ë¤Ä¤¤¤Æ¡¢9³ä¤Û¤É¤Î³ÎΨ¤Ç¡¢ÌÜ»ë´Ñ»¡¤È°ìÃפ¹¤ë·ë²Ì¤ò½Ð¤¹¤³¤È¤ËÀ®¸ù¤·¤¿¡£ÏÀʸ¤ÏƱ·î29Æü¡¢Proceedings of the Royal Society B: Biological Sciences»ï¤Ë·ÇºÜ¤µ¤ì¤¿¡£
|
¼çÍץХ¤¥ªÆõö¤ÎÅÐÏ¿¾ðÊó¡¢2023ǯ3·î15Æü¡Á3·î20Æüȯ¹Ôʬ¡ÊÅÐÏ¿Èֹ桦ȯÌÀ¤Î̾¾Î¡¦½Ð´ê¿Í¡¦Í×Ìó¡Ë from Æü·Ð¥Ð¥¤¥ª¥Æ¥¯ONLINE (2023-3-29 7:00) |
¡¡°ìÈ̼ÒÃÄË¡¿ÍȯÌÀ¿ä¿Ê¶¨²ñ¤¬È¯¹Ô¤¹¤ë¡ÖÆõö¸øÊó¡×2023ǯ3·î15Æü¡Á3·î20Æüȯ¹Ôʬ¤è¤ê¡¢¥Ð¥¤¥ª´ØÏ¢¤ÈȽÃǤǤ¤ë¼ç¤ÊÆõö¤ÎÅÐÏ¿¾ðÊó¤ò°Ê²¼¤Ë·ÇºÜ¤·¤Þ¤¹¡£
|